Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - ALBIREO PHARMA, INC. | y85453exv99w2.htm |
| EX-99.1 - EX-99.1 - ALBIREO PHARMA, INC. | y85453exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 6,2010
(June 25, 2010)
BIODEL INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-33451 | 90-0136863 | ||
| (State or Other Jurisdiction of Incorporation | (Commission File Number) |
(IRS Employer Identification No.) |
||
| 100 Saw Mill Road Danbury, Connecticut |
06810 |
|
| (Address of Principal Executive Offices) | (Zip Code) | |
| Registrant’s telephone number, including area code (203) 796-5000 |
100 Saw Mill Road, Danbury Connecticut 06810
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 8.01. Other Events
On June 25, 2010, Biodel Inc. (the “Company”) issued a press release announcing
the presentation of final results of the Company’s pivotal Phase 3 clinical trial comparing use of
VIAject® to regular human insulin in patients with type 2 diabetes at the American Diabetes
Association’s Annual Meeting in Orlando, Florida.
A copy of the foregoing press release is attached to this Current Report on Form 8-K as
Exhibit 99.1 and is incorporated herein by reference.
On
June 26, 2010, the Company issued a press release announcing the
report of poster
presentations demonstrating potential benefits of more-rapid-acting injectable insulins at the
Annual Meeting of the American Diabetes Association in Orlando, Florida.
A copy of the foregoing press release is attached to this Current Report on Form 8-K as
Exhibit 99.2 and is incorporated herein by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIODEL INC. |
||||
| Date: July 6, 2010 | By: | /s/ Gerard Michel | ||
| Gerard Michel | ||||
| Chief Financial Officer | ||||
Exhibit
Index
| Exhibit No. | Description | |
| 99.1 | Press Release issued by the Company on June 25, 2010. | |
| 99.2 | Press Release issued by the Company on June 26, 2010. |